Focus:
Central Nervous System
-
15 February 2019
Passage Bio receives $115m in funding to address CNS diseases
Gene therapy company Passage Bio has launched in the US with $115.5m series A funding to develop AAV-delivered therapies for the treatment of rare monogenic central nervous system (CNS) disorders.
-
14 February 2019 News
SK Biopharmaceuticals-Arvelle partner on epilepsy drug cenobamate in Europe
South Korea-based SK Biopharmaceuticals and Swiss Arvelle Therapeutics have signed an exclusive licensing agreement to develop and commercialise SK Biopharmaceuticals’ cenobamate in Europe.
-
13 February 2019 News
Dementia Consortium welcomes new partners to drug discovery collaboration
Charity industry partnership Dementia Consortium has announced that pharmaceutical companies, Johnson & Johnson Innovation, Takeda and research organisation Evotec have joined its drug discovery collaboration for neurodegenerative diseases.
-
7 February 2019 whitepapers
Pharma Application Leaflet for Diclofenac Sodium, Direct Compression
Diclofenac Sodium is a non-steroidal anti-inflammatory drug (NSAID) that is classified as an over-the-counter (OTC) product. It features Sigachi's microcrystalline cellulose (MCC) product HiCel 12 as a major excipient in...
-
25 January 2019 whitepapers
Case Study: Bristol-Myers Squibb
Bristol-Myers Squibb (BMS) is a global biopharmaceutical company headquartered in New York City that specialises in discovering, developing and delivering innovative medicines for patients with serious diseases.
-
22 January 2019 News
Antiepileptics linked to more hospital days in Alzheimer’s patients
A new study by the University of Eastern Finland has found that use of antiepileptic drugs can lead to more hospital days for people living with Alzheimer’s disease.
-
11 January 2019 News
Common medications for physical health may also treat mental illness
A large study led by University College London (UCL) has found that cheap, common physical health drugs could help treat serious mental illnesses (SMI) such as schizophrenia and bipolar disorder.
-
7 January 2019 News
Biogen signs two deals to address neurological disorders
Biogen has signed a strategic collaboration with US-based drug maker C4 Therapeutics for the discovery and development of new therapies to treat neurological diseases, including Alzheimer’s disease.
-
17 December 2018 Comment
Population aged 80-89 represents the majority of Alzheimer’s Cases
Across the US, 5EU (France, Germany, Italy, Spain, and UK), and Japan, there were over 10.5 million men and women ages 60 and older living with Alzheimer’s disease in 2016.
-
12 December 2018 News
Vect-Horus and Janssen partner for neurodegenerative disease treatment
Vect-Horus has entered a research collaboration agreement with Johnson & Johnson subsidiary Janssen Pharmaceuticals for treating neurodegenerative diseases.